Triden Special Precautions

Secondary causes of hyperlipidemia, such as uncontrolled type 2 diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemia, obstructive liver disease or alcoholism should be adequately treated before fenofibrate therapy is considered. Secondary caused of hypercholesterolemia related to pharmacological treatment can be seen with diuretics, β-blocking agents, estrogens, progestogens, combined oral contraceptives, immunosuppressive agents and protease inhibitors. In this cases it should be ascertained whether the hyperlipidaemia is of primary or secondary nature (possible elevation of lipid values caused by theses therapeutic agents).
Liver function: as with other lipid lowering agents, increases have been reported in transaminase levels are monitored every 3 months during the first 12 months of treatment and thereafter periodically. attention should be paid to patients who develop increase in transaminase levels and therapy should be discontinued is AST (SGOT) and ALT {SGPT) levels increase to more than 3 times the upper limit of the normal range. When symptoms indicative of hepatitis occurs (e.g. jaundice, pruritus), and diagnosis is confirmed by laboratory testing, fenofibrate therapy should be discontinued.
Pancreas: Pancreatitis has been reported in patients taking fenofibrate (see Contraindications and Adverse Reactions). This occurrence may present a failure of efficacy in patients with severe hypertriglyceridemia, a direct drug effect. or a secondary phenomenon mediated through biliary tract stone or sludge formation, resulting in the obstruction of the common bile duct.
Muscle: Muscle toxicity, including rare cases of rhabdomyolysis, with or without renal failure, has been reported with administration of fibrates and other lipid - lowering agents. The incidence of this disorder increases in cases of hypoalbuminaemia and previous renal insufficiency.
Patients with pre-disposing factors for myopathy and/or rhabdomyolysis, including age above 70 years old, personal or familial history of hereditary muscular disorders, renal impairment, hypothyroidism and high alcohol intake, may be at an increased risk of developing rhabdomyolysis. For these patients, the putative benefits and risks of fenofibrate therapy should be carefully weighed up.
Muscle toxicity should be suspected in patients presenting diffuse myalgia, myositis, muscular cramps and weakness and/or mark increases in CPK (levels exceeding 5 times the normal range). In such cases treatment with fenofibrate should be stopped.
The risk of muscle toxicity may be increased if the drug is administered with another fibrate or an HMG-CoA reductase inhibitor, especially in cases of pre-existing muscular disease. Consequently, the coprescription of fenofibrate with a HMG-CoA reductase inhibitor or another fibrate should be reserved to patients with severe combined dyslipidaemia and high cardiovascular risk without any history of muscular disease and with a close monitoring of potential muscle toxicity.
Renal function: Treatment should be interrupted in case of an increase in creatinine levels .50% ULN (upper limit of normal). it is recommended that creatinine is measured during the first 3 months after initiation of treatment and thereafter periodically (see Dosage & Administration).
Effects on Ability to Drive and Use Machines: Fenofibrate 160 mg, film-coated tablet has no or negligible influence on the ability to drive and use machines.